Allotransplantation for Patients Age >= 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

Brian L. McClune; Kwang Woo Ahn; Hai-Lin Wang; Joseph H. Antin; Andrew S. Artz; Jean-Yves Cahn; Abhinav Deol; Cesar O. Freytes; Mehdi Hamadani; Leona A. Holmberg; Madan H. Jagasia; Ann A. Jakubowski; Mohamed A. Kharfan-Dabaja; Hillard M. Lazarus; Alan M. Miller; Richard Olsson; Tanya L. Pedersen; Joseph Pidala; Michael A. Pulsipher; Jacob M. Rowe; Wael Saber; Koen W. van Besien; Edmund K. Waller; Mahmoud D. Aljurf; Goergun Akpek; Ulrike Bacher; Nelson J. Chao; Yi-Bin Chen; Brenda W. Cooper; Jason Dehn; Marcos J. de Lima; Jack W. Hsu; Ian D. Lewis; David I. Marks; Joseph McGuirk; Mitchell S. Cairo; Harry C. Schouten; Jeffrey Szer; Muthalagu Ramanathan; Bipin N. Savani; Matthew Seftel; Gerard Socie; Ravi Vij; Erica D. Warlick; Daniel J. Weisdorf

doi:10.1016/j.bbmt.2014.03.013

Allotransplantation for Patients Age >= 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

Brian L. McClune, Kwang Woo Ahn, Hai-Lin Wang, Joseph H. Antin, Andrew S. Artz, Jean-Yves Cahn, Abhinav Deol, Cesar O. Freytes, Mehdi Hamadani, Leona A. Holmberg, Madan H. Jagasia, Ann A. Jakubowski, Mohamed A. Kharfan-Dabaja, Hillard M. Lazarus, Alan M. Miller, Richard Olsson, Tanya L. Pedersen, Joseph Pidala, Michael A. Pulsipher, Jacob M. RoweWael Saber, Koen W. van Besien, Edmund K. Waller, Mahmoud D. Aljurf, Goergun Akpek, Ulrike Bacher, Nelson J. Chao, Yi-Bin Chen, Brenda W. Cooper, Jason Dehn, Marcos J. de Lima, Jack W. Hsu, Ian D. Lewis, David I. Marks, Joseph McGuirk, Mitchell S. Cairo, Harry C. Schouten, Jeffrey Szer, Muthalagu Ramanathan, Bipin N. Savani, Matthew Seftel, Gerard Socie, Ravi Vij, Erica D. Warlick, Daniel J. Weisdorf^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ?40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning HCT for aggressive (n = 668) or indolent (n = 580) NHL. Aggressive lymphoma was more frequent in the oldest cohort 49% for age 40 to 54 versus 57% for age 55 to 64 versus 67% for age ?65; P = .0008). Fewer patients aged ?65 had previous autografting (26% versus 24% versus 9%; P = .002). Rates of relapse, acute and chronic GVHD, and nonrelapse mortality (NRM) at 1 year post-HCT were similar in the 3 age cohorts (22% [95% confidence interval (CI), 19% to 26%] for age 40 to 54, 27% [95% CI, 23% to 31%] for age 55 to 64, and 34% [95% CI, 24% to 44%] for age ?65. Progression-free survival (PFS) and overall survival (OS) at 3 years was slightly lower in the older cohorts (OS: 54% [95% CI, 50% to 58%] for age 40 to 54; 40% [95% CI, 36% to 44%] for age 55 to 64, and 39% [95% CI, 28% to 50%] for age ?65; P <.0001). Multivariate analysis revealed no significant effect of age on the incidence of acute or chronic GVHD or relapse. Age ?55 years, Karnofsky Performance Status

Original language	English
Pages (from-to)	960-968
Journal	Biology of Blood and Marrow Transplantation
Volume	20
Issue number	7
DOIs	https://doi.org/10.1016/j.bbmt.2014.03.013
Publication status	Published - Jul 2014

Keywords

Reduced intensity
Nonmyeloablative
Allogeneic
Hematopoietic cell transplantation
Elderly
Lymphoma

Access to Document

10.1016/j.bbmt.2014.03.013Licence: CC BY-NC-ND

Cite this

McClune, B. L., Ahn, K. W., Wang, H.-L., Antin, J. H., Artz, A. S., Cahn, J.-Y., Deol, A., Freytes, C. O., Hamadani, M., Holmberg, L. A., Jagasia, M. H., Jakubowski, A. A., Kharfan-Dabaja, M. A., Lazarus, H. M., Miller, A. M., Olsson, R., Pedersen, T. L., Pidala, J., Pulsipher, M. A., ... Weisdorf, D. J. (2014). Allotransplantation for Patients Age >= 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. Biology of Blood and Marrow Transplantation, 20(7), 960-968. https://doi.org/10.1016/j.bbmt.2014.03.013

@article{c5e444a9e33d4f92a25d40f6b2e7c315,

title = "Allotransplantation for Patients Age >= 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival",

abstract = "Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ?40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning HCT for aggressive (n = 668) or indolent (n = 580) NHL. Aggressive lymphoma was more frequent in the oldest cohort 49% for age 40 to 54 versus 57% for age 55 to 64 versus 67% for age ?65; P = .0008). Fewer patients aged ?65 had previous autografting (26% versus 24% versus 9%; P = .002). Rates of relapse, acute and chronic GVHD, and nonrelapse mortality (NRM) at 1 year post-HCT were similar in the 3 age cohorts (22% [95% confidence interval (CI), 19% to 26%] for age 40 to 54, 27% [95% CI, 23% to 31%] for age 55 to 64, and 34% [95% CI, 24% to 44%] for age ?65. Progression-free survival (PFS) and overall survival (OS) at 3 years was slightly lower in the older cohorts (OS: 54% [95% CI, 50% to 58%] for age 40 to 54; 40% [95% CI, 36% to 44%] for age 55 to 64, and 39% [95% CI, 28% to 50%] for age ?65; P <.0001). Multivariate analysis revealed no significant effect of age on the incidence of acute or chronic GVHD or relapse. Age ?55 years, Karnofsky Performance Status ",

keywords = "Reduced intensity, Nonmyeloablative, Allogeneic, Hematopoietic cell transplantation, Elderly, Lymphoma",

author = "McClune, {Brian L.} and Ahn, {Kwang Woo} and Hai-Lin Wang and Antin, {Joseph H.} and Artz, {Andrew S.} and Jean-Yves Cahn and Abhinav Deol and Freytes, {Cesar O.} and Mehdi Hamadani and Holmberg, {Leona A.} and Jagasia, {Madan H.} and Jakubowski, {Ann A.} and Kharfan-Dabaja, {Mohamed A.} and Lazarus, {Hillard M.} and Miller, {Alan M.} and Richard Olsson and Pedersen, {Tanya L.} and Joseph Pidala and Pulsipher, {Michael A.} and Rowe, {Jacob M.} and Wael Saber and {van Besien}, {Koen W.} and Waller, {Edmund K.} and Aljurf, {Mahmoud D.} and Goergun Akpek and Ulrike Bacher and Chao, {Nelson J.} and Yi-Bin Chen and Cooper, {Brenda W.} and Jason Dehn and {de Lima}, {Marcos J.} and Hsu, {Jack W.} and Lewis, {Ian D.} and Marks, {David I.} and Joseph McGuirk and Cairo, {Mitchell S.} and Schouten, {Harry C.} and Jeffrey Szer and Muthalagu Ramanathan and Savani, {Bipin N.} and Matthew Seftel and Gerard Socie and Ravi Vij and Warlick, {Erica D.} and Weisdorf, {Daniel J.}",

year = "2014",

month = jul,

doi = "10.1016/j.bbmt.2014.03.013",

language = "English",

volume = "20",

pages = "960--968",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Science",

number = "7",

}

McClune, BL, Ahn, KW, Wang, H-L, Antin, JH, Artz, AS, Cahn, J-Y, Deol, A, Freytes, CO, Hamadani, M, Holmberg, LA, Jagasia, MH, Jakubowski, AA, Kharfan-Dabaja, MA, Lazarus, HM, Miller, AM, Olsson, R, Pedersen, TL, Pidala, J, Pulsipher, MA, Rowe, JM, Saber, W, van Besien, KW, Waller, EK, Aljurf, MD, Akpek, G, Bacher, U, Chao, NJ, Chen, Y-B, Cooper, BW, Dehn, J, de Lima, MJ, Hsu, JW, Lewis, ID, Marks, DI, McGuirk, J, Cairo, MS, Schouten, HC, Szer, J, Ramanathan, M, Savani, BN, Seftel, M, Socie, G, Vij, R, Warlick, ED & Weisdorf, DJ 2014, 'Allotransplantation for Patients Age >= 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival', Biology of Blood and Marrow Transplantation, vol. 20, no. 7, pp. 960-968. https://doi.org/10.1016/j.bbmt.2014.03.013

TY - JOUR

T1 - Allotransplantation for Patients Age >= 40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival

AU - McClune, Brian L.

AU - Ahn, Kwang Woo

AU - Wang, Hai-Lin

AU - Antin, Joseph H.

AU - Artz, Andrew S.

AU - Cahn, Jean-Yves

AU - Deol, Abhinav

AU - Freytes, Cesar O.

AU - Hamadani, Mehdi

AU - Holmberg, Leona A.

AU - Jagasia, Madan H.

AU - Jakubowski, Ann A.

AU - Kharfan-Dabaja, Mohamed A.

AU - Lazarus, Hillard M.

AU - Miller, Alan M.

AU - Olsson, Richard

AU - Pedersen, Tanya L.

AU - Pidala, Joseph

AU - Pulsipher, Michael A.

AU - Rowe, Jacob M.

AU - Saber, Wael

AU - van Besien, Koen W.

AU - Waller, Edmund K.

AU - Aljurf, Mahmoud D.

AU - Akpek, Goergun

AU - Bacher, Ulrike

AU - Chao, Nelson J.

AU - Chen, Yi-Bin

AU - Cooper, Brenda W.

AU - Dehn, Jason

AU - de Lima, Marcos J.

AU - Hsu, Jack W.

AU - Lewis, Ian D.

AU - Marks, David I.

AU - McGuirk, Joseph

AU - Cairo, Mitchell S.

AU - Schouten, Harry C.

AU - Szer, Jeffrey

AU - Ramanathan, Muthalagu

AU - Savani, Bipin N.

AU - Seftel, Matthew

AU - Socie, Gerard

AU - Vij, Ravi

AU - Warlick, Erica D.

AU - Weisdorf, Daniel J.

PY - 2014/7

Y1 - 2014/7

N2 - Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ?40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning HCT for aggressive (n = 668) or indolent (n = 580) NHL. Aggressive lymphoma was more frequent in the oldest cohort 49% for age 40 to 54 versus 57% for age 55 to 64 versus 67% for age ?65; P = .0008). Fewer patients aged ?65 had previous autografting (26% versus 24% versus 9%; P = .002). Rates of relapse, acute and chronic GVHD, and nonrelapse mortality (NRM) at 1 year post-HCT were similar in the 3 age cohorts (22% [95% confidence interval (CI), 19% to 26%] for age 40 to 54, 27% [95% CI, 23% to 31%] for age 55 to 64, and 34% [95% CI, 24% to 44%] for age ?65. Progression-free survival (PFS) and overall survival (OS) at 3 years was slightly lower in the older cohorts (OS: 54% [95% CI, 50% to 58%] for age 40 to 54; 40% [95% CI, 36% to 44%] for age 55 to 64, and 39% [95% CI, 28% to 50%] for age ?65; P <.0001). Multivariate analysis revealed no significant effect of age on the incidence of acute or chronic GVHD or relapse. Age ?55 years, Karnofsky Performance Status

AB - Non-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often undergo allogeneic hematopoietic cell transplantation (HCT). We analyzed Center for International Blood and Marrow Transplant Research data on 1248 patients age ?40 years receiving reduced-intensity conditioning (RIC) or nonmyeloablative (NMA) conditioning HCT for aggressive (n = 668) or indolent (n = 580) NHL. Aggressive lymphoma was more frequent in the oldest cohort 49% for age 40 to 54 versus 57% for age 55 to 64 versus 67% for age ?65; P = .0008). Fewer patients aged ?65 had previous autografting (26% versus 24% versus 9%; P = .002). Rates of relapse, acute and chronic GVHD, and nonrelapse mortality (NRM) at 1 year post-HCT were similar in the 3 age cohorts (22% [95% confidence interval (CI), 19% to 26%] for age 40 to 54, 27% [95% CI, 23% to 31%] for age 55 to 64, and 34% [95% CI, 24% to 44%] for age ?65. Progression-free survival (PFS) and overall survival (OS) at 3 years was slightly lower in the older cohorts (OS: 54% [95% CI, 50% to 58%] for age 40 to 54; 40% [95% CI, 36% to 44%] for age 55 to 64, and 39% [95% CI, 28% to 50%] for age ?65; P <.0001). Multivariate analysis revealed no significant effect of age on the incidence of acute or chronic GVHD or relapse. Age ?55 years, Karnofsky Performance Status

KW - Reduced intensity

KW - Nonmyeloablative

KW - Allogeneic

KW - Hematopoietic cell transplantation

KW - Elderly

KW - Lymphoma

U2 - 10.1016/j.bbmt.2014.03.013

DO - 10.1016/j.bbmt.2014.03.013

M3 - Article

C2 - 24641829

SN - 1083-8791

VL - 20

SP - 960

EP - 968

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 7

ER -